Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

407 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.
Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS; ADAURA Investigators. Wu YL, et al. Among authors: de marinis f. N Engl J Med. 2020 Oct 29;383(18):1711-1723. doi: 10.1056/NEJMoa2027071. Epub 2020 Sep 19. N Engl J Med. 2020. PMID: 32955177 Clinical Trial.
Application of nnU-Net for Automatic Segmentation of Lung Lesions on CT Images and Its Implication for Radiomic Models.
Ferrante M, Rinaldi L, Botta F, Hu X, Dolp A, Minotti M, De Piano F, Funicelli G, Volpe S, Bellerba F, De Marco P, Raimondi S, Rizzo S, Shi K, Cremonesi M, Jereczek-Fossa BA, Spaggiari L, De Marinis F, Orecchia R, Origgi D. Ferrante M, et al. Among authors: de marinis f, de marco p, de piano f. J Clin Med. 2022 Dec 9;11(24):7334. doi: 10.3390/jcm11247334. J Clin Med. 2022. PMID: 36555950 Free PMC article.
Brain metastases from NSCLC treated with stereotactic radiotherapy: prediction mismatch between two different radiomic platforms.
Carloni G, Garibaldi C, Marvaso G, Volpe S, Zaffaroni M, Pepa M, Isaksson LJ, Colombo F, Durante S, Lo Presti G, Raimondi S, Spaggiari L, de Marinis F, Piperno G, Vigorito S, Gandini S, Cremonesi M, Positano V, Jereczek-Fossa BA. Carloni G, et al. Among authors: de marinis f. Radiother Oncol. 2023 Jan;178:109424. doi: 10.1016/j.radonc.2022.11.013. Epub 2022 Nov 24. Radiother Oncol. 2023. PMID: 36435336
Actionable driver gene alterations in early-stage non-small cell lung cancer: a review.
Attili I, Pisapia P, Spitaleri G, Aliaga PT, Del Signore E, Napoli VM, Passaro A, Malapelle U, Troncone G, de Marinis F. Attili I, et al. Among authors: de marinis f. Ther Adv Med Oncol. 2026 Jan 17;18:17588359251414117. doi: 10.1177/17588359251414117. eCollection 2026. Ther Adv Med Oncol. 2026. PMID: 41555859 Free PMC article. Review.
Crizotinib in Patients With ROS1-Positive NSCLC With or Without Brain Metastases: Post Hoc Analysis of Phase II METROS Trial.
Landi L, Chiari R, Tiseo M, Metro G, de Marinis F, Delmonte A, Novello S, Cortinovis DL, Galetta D, Bonanno L, Gridelli C, Morabito A, Grossi F, Torchia A, Giannarelli D, Borra G, Mazzoni F, Pilotto S, Cappuzzo F. Landi L, et al. Among authors: de marinis f. JTO Clin Res Rep. 2025 Sep 17;6(12):100909. doi: 10.1016/j.jtocrr.2025.100909. eCollection 2025 Dec. JTO Clin Res Rep. 2025. PMID: 41278398 Free PMC article.
Plain language summary of the ALINA study results: alectinib compared with chemotherapy after surgery in people with ALK-positive non-small cell lung cancer.
Wu YL, Dziadziuszko R, Ahn JS, Barlesi F, Nishio M, Lee DH, Lee JS, Zhong W, Horinouchi H, Mao W, Hochmair M, de Marinis F, Migliorino MR, Bondarenko I, Lu S, Wang Q, Lohmann TO, Xu T, Cardona A, Hiles L, Noe J, Solomon BJ. Wu YL, et al. Among authors: de marinis f. Future Sci OA. 2025 Dec;11(1):2578145. doi: 10.1080/20565623.2025.2578145. Epub 2025 Nov 11. Future Sci OA. 2025. PMID: 41217067 Free PMC article.
EORTC 1417 - REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer.
Menis J, Greiller L, Demontrond P, Monnet I, Novello S, Livi L, Young R, Decroisette C, Cloarec N, Robinet G, Schott R, Fayette J, Banna GL, De Marinis F, Califano R, Duchemann B, Luciani A, Colantonio I, Fournier B, Pretzenbacher Y, Caramella C, Silva M, Berghmans T, Dingemans AM, Bironzo P, Tugwood J, Zhou C, Hill S, Bradbury K, Morris K, Kilgour E, Dive C, Blackhall F, Besse B. Menis J, et al. Among authors: de marinis f. Eur J Cancer. 2025 Dec 9;231:116059. doi: 10.1016/j.ejca.2025.116059. Epub 2025 Oct 30. Eur J Cancer. 2025. PMID: 41192233 Clinical Trial.
Actionable Gene Alterations in Resected Non-Small Cell Lung Cancer: Primary Results From the AGA-R Study.
Attili I, Pellizzari G, Bertolaccini L, Corvaja C, Vacirca D, Lombardi M, Spitaleri G, Trillo Aliaga P, Del Signore E, Passaro A, Guarize J, Guerini-Rocco E, Fusco N, Spaggiari L, de Marinis F. Attili I, et al. Among authors: de marinis f. Clin Lung Cancer. 2025 Oct 3:S1525-7304(25)00240-2. doi: 10.1016/j.cllc.2025.09.015. Online ahead of print. Clin Lung Cancer. 2025. PMID: 41173737
Long-term Survival Analysis From PERLA, A Phase II Randomized Trial of Dostarlimab With Chemotherapy Versus Pembrolizumab With Chemotherapy in Metastatic Nonsquamous NSCLC.
Lim SM, Ortega Granados AL, Pinto GDJ, Fuentes CS, Lo Russo G, Schenker M, Ahn JS, de Marinis F, Locke K Jr, Szijgyarto Z, Buss E, Stjepanovic N, Diaz-Padilla I, Peters S. Lim SM, et al. Among authors: de marinis f. JTO Clin Res Rep. 2025 Sep 4;6(10):100900. doi: 10.1016/j.jtocrr.2025.100900. eCollection 2025 Oct. JTO Clin Res Rep. 2025. PMID: 41080090 Free PMC article.
407 results